However, in our breaking investigation, we found hundreds of millions of dollars in payments also flow the other way. These are royalty payments from third-party payers (think pharmaceutical companies) back to the NIH and individual NIH scientists.
We estimate that between fiscal years 2010 and 2020, more than $350 million in royalties were paid by third-parties to the agency and NIH scientists – who are credited as co-inventors.